- Antimicrobial resistance (AMR) is projected to cause 10 million deaths annually by 2050.
- Misuse of antibiotics onboard ships exacerbates AMR, a “silent pandemic.”
- Limited access to professional healthcare onboard increases seafarers’ vulnerability.
- The stagnant development pipeline of new antibiotics compounds the crisis.
- Maritime industry solutions include telemedicine, crew training, and stricter antibiotic use protocols.
Antimicrobial resistance (AMR) poses a significant global health challenge, with Safety4Sea reporting that it may result in 10 million deaths annually by 2050. This “silent pandemic” is particularly concerning for seafarers, whose confined and resource-limited environment heightens their vulnerability to infections.
AMR: A Global Crisis in the Making
Ranked as the third most lethal infectious condition after COVID-19 and tuberculosis, AMR already claims more lives annually than HIV and malaria. According to Shyam Bishen, head of the Centre for Health and Healthcare at the World Economic Forum, AMR could soon become one of the top 10 global causes of death.
AMR develops when pathogens adapt to evade antibiotics, rendering treatments ineffective. Misuse of antibiotics onboard—commonly for viral infections like colds or flu—accelerates resistance, compromising future treatment efficacy and complicating medical care.
A Stagnant Innovation Pipeline
Compounding the crisis is a near-halt in antibiotic development. The World Health Organization (WHO) reports only 27 antibiotics in clinical trials, with a mere six considered innovative. Global shortages of approved antibiotics further exacerbate the challenge, underlining the urgent need for increased investment in research and equitable access to medications.
The Maritime Perspective
Seafarers face unique challenges regarding AMR due to their isolated environment and limited access to professional healthcare. Ships’ Masters often make medical decisions without adequate training, leading to inappropriate antibiotic use. This misuse not only fails to treat illnesses effectively but also increases resistance and side effects.
Dr. Jens Tülsner, CEO of Marine Medical Solutions, highlighted the risks:“Improper use of antibiotics fails to address illnesses like colds or flu and can cause unnecessary side effects. Telemedical support can play a key role in guiding better medical practices onboard.”
Recommendations for the Maritime Industry
To mitigate AMR, the maritime industry must adopt targeted measures:
- Leverage Telemedicine
Equip vessels with telemedical consultation capabilities to provide expert guidance on appropriate antibiotic use. - Enhance Crew Training
Educate seafarers on distinguishing bacterial infections from viral illnesses and the responsible use of antibiotics. - Establish Clear Protocols
Develop strict guidelines for antibiotic use, restricting self-prescription practices onboard. - Support Global Innovation
Advocate for investments in antibiotic research and ensure equitable access to effective medications targeting resistant bacteria. - Sustain Political Advocacy
Use international platforms like the G7 and United Nations to maintain AMR as a global health priority.
Time to Act: The Maritime Industry’s Role
AMR is responsible for over 1 million direct deaths annually, with nearly 5 million linked indirectly. The COVID-19 pandemic underscored the gravity of the issue, with widespread misuse of antibiotics for viral infections. Global leaders are beginning to act, with initiatives like the European Union’s “One Health” approach connecting human, animal, and environmental health.
For the maritime industry, addressing AMR ensures seafarers’ well-being, protects global trade continuity, and contributes to the broader fight against this global health crisis. By promoting responsible practices, leveraging professional medical advice, and supporting innovation, the maritime community can be pivotal in combating AMR.
Did you Subscribe to our daily newsletter?
It’s Free Click here to Subscribe!
Source: safety4sea
